IJMPD | A retrospective study on ovarian cancer with a median follow-up of 36 months at Bejaïa University Hospital

Indexing and Abstracting

A retrospective study on ovarian cancer with a median follow-up of 36 months at Bejaïa University Hospital

Chahira MAZOUZI , Radia BENYAHIA , Boualem BELLOUSE , Esma KERBOUA , Najet FERRAH , Rachida AFTIS

International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-7,Issue-5, October - December 2023, Pages 20-24 , 10.22161/ijmpd.7.5.4

Download | Downloads : 4 | Total View : 269

Article Info: Received: 02 Nov 2023; Received in revised form: 07 Dec 2023; Accepted: 14 Dec 2023; Available online: 21 Dec 2023 ©2023 The Author(s). Published by AI Publications. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)

Abstract:

Ovarian cancer is relatively common but serious and has a poor prognosis. The aim of this study is to highlight the epidemiological, diagnostic, therapeutic and evolutionary aspects of this malignant pathology managed at the Bejaia university hospital center. This is a retrospective and descriptive study over a period of 3 years (2019 - 2022) carried out on 20 patients who developed ovarian cancer. The average age of the patients was 50 years old, 53.23% of whom were over 45 years old. The CA-125 blood test was positive in 18 out of 20 patients. The tumors were discovered on ultrasound in 87.10% of cases and at laparotomy in 12.90%. Total hysterectomy with bilateral adnexectomy was the most performed procedure (64.52%). The early postoperative course was simple. 15 patients underwent second look surgery (16.13%) for locoregional recurrences. Epithelial tumors were the most frequent histological type (93.55%), including 79% in the advanced stage ( IIIc -IV) and 21% in the early stage (Ia- Ib ). Adjuvant chemotherapy was administered in 80% of patients. With a median follow-up of 36 months, 2 patients were lost to follow-up. The evolution was favorable in 27.42% and in 25.81% deaths occurred late postoperatively. Ovarian cancer is not common but serious given the advanced stages and the high rate of late postoperative deaths which were largely observed in patients deprived of adequate neoadjuvant or adjuvant chemotherapy.

Keywords:

Ovarian Cancer, Epidemiology, Diagnostic Procedures, Treatment Modalities, Prognosis and Survival

References:

[1] INSP 2019 Algeria
[2] Ovarian cancer, five- year stage specific relative Survival rates, J. Natl. Cancer Institute , vol.103, p.1287, 2004.
[3] R. De- angelis, Cancer survival in Europe 1999-2007 by country and age : results of EUROCARE--5-a population- based study , Lancet Oncol , vol.15, pp.23-34, 2014.
[4] C. Sun, The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer : A Systematic Review of the Literature with a Meta- Analysis , PLoS ONE, vol.9, p.95285, 2014.
[5] Trétarre B, Remontet L, Ménégoz F, Mace- Lesec'h J, Grosclaude P, Buemi A, et al. Ovarian cancer : incidence and mortality in France. J Gynecol Obstet Biol Reprod . 2005 ; 34:154–61.
[6] Argento M, Hoffman P, Gauchez AS. Ovarian cancer and the prospects for improving early diagnosis. Immuno -analysis and specialized biology. 2008 ; 23:251–9.
[7] Le Roux C, Sentilhes L, Catala L, Lefebvre- Lacoeuille C, Poilblanc M, Descamps P. Laparoscopy for surgical treatment for uterine and ovarian cancer in France : a national practice survey . J Gynecol Obstet Biol Reprod . 2011 ; 40(3) :231–6.
[8] Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009 ; 374:1371–82.
[9] Ferlay J, Bray F, Pisani P, Parkin DM. Lyon : IARC Press ; Globocan 2000 : Cancer incidence, mortality and prevalence worldwide .
[10] Benoit L, Désir JP, Fraisse J, Arnould L, Cuisenier J. Evolution of therapeutic practices and survival of ovarian cancer in Bourgandi between 1982-1996 : a registry-based study . Ann Chir. 2004 ; 129(8) :415–21.
[11] Chene G, Penault-Llorca F, Robin N, Cayre A, Provencher DM, Dauplat J. Early detection of ovarian cancer : tomorrow ? A review . J Gynecol Obstet Biol Reprod . 2013 ; 42(1) :5–11.
[12] US. Preventive Services Task Force Screening for ovarian cancer : recommendation statement. Ann Fam Med. 2004 ; 2:260–2.